PHILADELPHIA, PA — Century Therapeutics, Inc. (NASDAQ: IPSC) has cemented a collaboration with renowned cell therapy leaders Professors Georg Schett and Andreas Mackensen to initiate a Phase 1/2 trial ...

Sex-related differences in pulmonary complications were found among men vs women with SSc, specifically in the prevalence of ILD and SAD.

PHILADELPHIA - Century Therapeutics, Inc. (NASDAQ: IPSC), a biotechnology firm with a market capitalization of $77.32 million ...

Century Therapeutics (IPSC) has entered into an agreement for an investigator-initiated Phase 1/2 trial by Professors Georg Schett and Andreas ...